Anzeige
Mehr »
Login
Sonntag, 19.01.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
SaRevolution Med shoots for $100M+ IPO - and divulges some secrets about that Warp Drive buyout
FrAt JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell
FrPeter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO
FrIntercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel
FrChina's fourth richest man takes a back seat at the top drugmaker he built
FrNovo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
FrIn active shopping mode, Eli Lilly plots one deal per quarter as it scouts 'Dermira-like' assets up to $5B
FrFirst Chinese biotech on Nasdaq in two years draws $104M
FrGermany's IQWiG finds first tumor-agnostic drug provides no added benefit
FrHung jury vote leaves FDA with a difficult decision on Durect's non-opioid painkiller
FrBioMarin execs discuss some eye-popping numbers for the price of valrox - but haven't we heard this before?
DoJPM20: Five years after first PCSK9, Novartis goes for win as Sanofi moves on, Amgen salvages what's left
DoMayo Clinic launches clinical analytics platform with nference; WuXi buys German plant from Bayer
DoThe FDA: Faster, but not necessarily stronger - analysis finds
DoJPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of a mammoth fund debut
DoFrazier closes 10th fund in 30 years, with $617M to bet on cell/gene therapy, Big Pharma spinoffs and more
DoNeon Therapeutics makes one last retreat, selling itself cheap in a bargain basement M&A deal
DoBiopharma's China plan gets a boost from patent protections sealed in now official trade deal
DoGovernment spending bill tweak means 3 more NDAs will become BLAs, FDA says
DoGSK, Pfizer contradict on the future of consumer health JV - report
DoJPM20: After Year of NASH collapses, all eyes on two biotechs
MiVideo Replay: Endpoints at JPM20 - newsmakers on dealmaking, pricing and manufacturing
MiCelgene exec jumps to head bluebird bio ops in Europe, where its $1.8M gene therapy Zynteglo is now available
MiFDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing
MiFDA staff offer few clues on their stance on Durect's pain drug